https://mindmedicinelaw.com/briefing/clearmind-s-fda-submission-psychedelic-policy-dialogue-in-the-u-s-20261007-47786The Psychedelic Journalen2026-10-07T22:04:45.003925+00:00Clearmind’s FDA Submission: Psychedelic Policy Dialogue in the U.S.clearmind, fda, psychedelic policy, industry engagement, psychedelic regulation, clinical trials, u.s. federal law, drug development, public health, private sectorhttps://mindmedicinelaw.com/briefing/clearmind-s-psychedelic-therapy-recommendations-fda-policy-engagement-in-the-us-20261007-47626The Psychedelic Journalen2026-10-07T15:06:47.670175+00:00Clearmind’s Psychedelic Therapy Recommendations: FDA Policy Engagement in the USclearmind, fda policy, psychedelic therapy, industry submissions, us regulatory framework, drug development guidance, clinical trials, stakeholder engagementhttps://mindmedicinelaw.com/briefing/usc-launches-psilocybin-mindfulness-trial-for-depression-20261007-47628The Psychedelic Journalen2026-10-07T15:06:00.251441+00:00USC Launches Psilocybin-Mindfulness Trial for Depressionusc psilocybin trial, mindfulness and psychedelics, depression clinical research, psychedelic-assisted therapy, fda breakthrough therapy, academic psychedelic research, mental health policy, clinical trial protocolshttps://mindmedicinelaw.com/briefing/intranasal-penk-mscs-show-promise-for-opioid-dependence-in-rats-20261006-47563The Psychedelic Journalen2026-10-07T15:07:05.441283+00:00Intranasal PENK-MSCs Show Promise for Opioid Dependence in Ratsproenkephalin, mesenchymal stem cells, intranasal delivery, morphine dependence, neurotrophic factors, addiction treatment, preclinical research, substance use disorder, cell-based therapyhttps://mindmedicinelaw.com/briefing/ketamine-s-distinct-short-term-effects-on-insomnia-and-anxiety-in-trd-20261006-47561The Psychedelic Journalen2026-10-07T15:06:14.654925+00:00Ketamine’s Distinct Short-Term Effects on Insomnia and Anxiety in TRDketamine, treatment-resistant depression, insomnia, anxiety, clinical trial, psychiatric protocols, sleep mechanisms, FDA regulation, symptom-specific effectshttps://mindmedicinelaw.com/briefing/group-psychedelic-assisted-therapy-evidence-gaps-and-policy-implications-20261006-47516The Psychedelic Journalen2026-10-07T15:05:23.865407+00:00Group Psychedelic-Assisted Therapy: Evidence, Gaps, and Policy Implicationsgroup psychedelic therapy, systematic review, mental health, cost-effectiveness, peer support, randomized controlled trials, policy implications, clinical protocols, equity in therapy, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/optimi-health-s-phase-2-psilocybin-trial-advances-amid-market-pullback-20261006-47465The Psychedelic Journalen2026-10-06T22:06:52.473603+00:00Optimi Health’s Phase 2 Psilocybin Trial Advances Amid Market Pullbackoptimi health, psilocybin trial, phase 2 clinical trial, psychedelic sector, canadian regulation, market sentiment, health canada, investor risk, drug development, clinical research fundinghttps://mindmedicinelaw.com/briefing/ketamine-vs-esketamine-in-trd-clinical-policy-and-access-implications-20261006-47466The Psychedelic Journalen2026-10-06T22:06:31.352375+00:00Ketamine vs Esketamine in TRD: Clinical, Policy, and Access Implicationsketamine, esketamine, treatment-resistant depression, TRD, FDA approval, reimbursement, clinical trials, psychiatry, risk evaluation, real-world evidencehttps://mindmedicinelaw.com/briefing/dea-unveils-new-registration-forms-for-medical-cannabis-entities-20261006-47468The Psychedelic Journalen2026-10-06T22:05:27.272627+00:00DEA Unveils New Registration Forms for Medical Cannabis Entitiesdea registration, medical marijuana, federal oversight, cannabis policy, psychedelic regulation, compliance requirements, controlled substances, research licensing, diversion prevention, schedule ihttps://mindmedicinelaw.com/briefing/fda-eases-510-k-rules-for-toxicology-devices-impacts-for-psychedelic-testing-20261006-47248The Psychedelic Journalen2026-10-06T15:06:08.815434+00:00FDA Eases 510(k) Rules for Toxicology Devices—Impacts for Psychedelic Testingfda, 510(k) exemption, clinical toxicology, psychedelic research, device regulation, clinical trials, assay development, policy change, laboratory testing, public healthhttps://mindmedicinelaw.com/briefing/fda-requests-input-on-ibogaine-trial-design-for-oud-and-ptsd-20261006-47220The Psychedelic Journalen2026-10-06T15:05:36.846485+00:00FDA Requests Input on Ibogaine Trial Design for OUD and PTSDfda, ibogaine, clinical trial design, opioid use disorder, ptsd, psychedelic regulation, safety monitoring, public docket, federal research, policyhttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-for-cancer-related-anxiety-evidence-and-policy-outl-20261005-47520The Psychedelic Journalen2026-10-07T15:07:22.155343+00:00Psychedelic-Assisted Therapy for Cancer-Related Anxiety: Evidence and Policy Outlookpsychedelic-assisted therapy, cancer-related anxiety, integrative oncology, clinical trials, mental health guidelines, psilocybin, emerging therapies, regulatory policy, methodological challengeshttps://mindmedicinelaw.com/briefing/amygdala-and-anxiety-threat-probability-not-uncertainty-drives-neural-response-20261005-47564The Psychedelic Journalen2026-10-07T15:06:31.170553+00:00Amygdala and Anxiety: Threat Probability, Not Uncertainty, Drives Neural Responseamygdala function, threat probability, anxiety neurobiology, clinical trial design, biomarker development, psychedelic research, extended amygdala, BST, Ce, translational neurosciencehttps://mindmedicinelaw.com/briefing/multidose-psilocybin-for-ocd-johns-hopkins-open-label-trial-insights-20261005-47518The Psychedelic Journalen2026-10-07T15:05:43.882804+00:00Multidose Psilocybin for OCD: Johns Hopkins Open-Label Trial Insightspsilocybin, obsessive-compulsive disorder, johns hopkins, clinical trial, multidose protocol, psychedelic therapy, y-bocs, regulatory pathways, safety and efficacy, treatment-resistant ocdhttps://mindmedicinelaw.com/briefing/ketamine-research-in-perioperative-neurocognitive-disorders-global-trends-and-ga-20261005-47388The Psychedelic Journalen2026-10-06T22:07:47.762615+00:00Ketamine Research in Perioperative Neurocognitive Disorders: Global Trends and Gapsketamine, perioperative neurocognitive disorders, esketamine, postoperative delirium, clinical trials, research standardization, bibliometric analysis, international collaboration, anesthesia, neurocognitive outcomeshttps://mindmedicinelaw.com/briefing/therapists-insights-on-psilocybin-assisted-depression-therapy-rct-preprint-revie-20261005-47389The Psychedelic Journalen2026-10-06T22:07:31.827498+00:00Therapists’ Insights on Psilocybin-Assisted Depression Therapy: RCT Preprint Reviewpsilocybin therapy, major depressive disorder, therapist perspectives, randomized controlled trial, psychotherapeutic support, clinical practice, qualitative research, policy implications, training standardshttps://mindmedicinelaw.com/briefing/iv-ketamine-for-suicidal-trd-real-world-case-series-insights-bangladesh-2024-20261005-47400The Psychedelic Journalen2026-10-06T22:07:13.179961+00:00IV Ketamine for Suicidal TRD: Real-World Case Series Insights (Bangladesh, 2024)iv ketamine, treatment-resistant depression, suicidal ideation, case series, real-world evidence, personalized psychiatry, bangladesh, clinical protocols, psychedelic research, safety and efficacyhttps://mindmedicinelaw.com/briefing/caution-in-psychedelic-therapy-adoption-clinical-evidence-gaps-20261005-47354The Psychedelic Journalen2026-10-06T22:05:48.601189+00:00Caution in Psychedelic Therapy Adoption: Clinical Evidence Gapspsychedelic clinical trials, implementation science, psilocybin, MDMA, psychiatric interventions, evidence-based medicine, safety monitoring, comparative effectiveness, policy implications, mental healthhttps://mindmedicinelaw.com/briefing/eeg-aperiodic-activity-as-biomarker-implications-for-psychiatric-trials-20261004-47401The Psychedelic Journalen2026-10-06T22:08:10.147860+00:00EEG Aperiodic Activity as Biomarker: Implications for Psychiatric Trialseeg biomarkers, aperiodic activity, psychiatric disorders, schizophrenia, depression, bipolar disorder, psychedelic clinical trials, biomarker validation, regulatory sciencehttps://mindmedicinelaw.com/briefing/esketamine-vs-off-label-ketamine-u-s-regulatory-divide-deepens-20261003-47308The Psychedelic Journalen2026-10-06T15:06:24.149135+00:00Esketamine vs. Off-Label Ketamine: U.S. Regulatory Divide Deepensesketamine, ketamine clinics, off-label use, fda approval, psychedelic policy, insurance coverage, legal risk, rems program, clinical guidelines, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/ketamine-misuse-in-sexual-assaults-legal-and-public-health-risks-in-the-u-s-20261002-47469The Psychedelic Journalen2026-10-06T22:06:09.588532+00:00Ketamine Misuse in Sexual Assaults: Legal and Public Health Risks in the U.S.ketamine, sexual assault, public health, regulatory oversight, dissociative anesthetics, controlled substances, clinical safeguards, forensic toxicology, university policyhttps://mindmedicinelaw.com/briefing/astrocytic-p2x7-receptors-and-depression-implications-for-novel-antidepressant-s-20261001-47398The Psychedelic Journalen2026-10-06T22:08:27.268559+00:00Astrocytic P2X7 Receptors and Depression: Implications for Novel Antidepressant Strategiesastrocytic p2x7 receptors, depression, major depressive disorder, mouse model, electroacupuncture, glial targets, neuropsychiatric research, biomarkers, psychedelic mechanisms, clinical translationhttps://mindmedicinelaw.com/briefing/psychedelic-compound-reduces-chemotherapy-induced-neuropathy-new-evidence-20260929-47305The Psychedelic Journalen2026-10-06T15:05:53.371089+00:00Psychedelic Compound Reduces Chemotherapy-Induced Neuropathy: New Evidencepsychedelic research, chemotherapy-induced neuropathy, oncology supportive care, neuroprotection, clinical trials, FDA regulation, psychedelic compounds, cancer pain management, neuroinflammation, public health policyhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-spatial-working-memory-implications-for-clinical-trials-and-20260928-47303The Psychedelic Journalen2026-10-06T15:06:37.074564+00:00Ketamine’s Impact on Spatial Working Memory: Implications for Clinical Trials and Policyketamine, spatial working memory, cognitive effects, clinical trial design, neuroimaging, NMDA receptor, psychiatric safety, regulatory policy, cognitive risk, psychedelic research